Editas Medicine (EDIT) Tops Q3 EPS by 25c; Cash and Cash Equivalents of $657.0M

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. XYZ
8. SWKS
9. FISV
10. CVS

Go back to Editas Medicine (EDIT) Tops Q3 EPS by 25c; Cash and Cash Equivalents of $657.0M

Editas Medicine Announces Third Quarter 2021 Results and Business Updates

November 8, 2021 7:00 AM EST

EDIT-101 Phase 1/2 BRILLIANCE trial initial clinical data demonstrated favorable safety profile and preliminary evidence of clinical benefit; enrollment ongoing in adult high-dose and pediatric mid-dose cohorts

EDIT-301 Phase 1/2 RUBY trial for the treatment of sickle cell disease currently enrolling study participants

Presented preclinical data on novel SLEEK gene editing technology enabling high efficiency, multi-transgene knock-in in multiple clinically relevant cell types

CAMBRIDGE, Mass., , Nov. 08, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported... More